Innoviva Price to Free Cash Flow Ratio 2006-2020 | INVA

Historical price to free cash flow ratio values for Innoviva (INVA) since 2006.
Innoviva Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2020-08-07 13.51 2.27
2020-06-30 13.98 $5.95 2.35
2020-03-31 11.76 $5.77 2.04
2019-12-31 14.16 $5.80 2.44
2019-09-30 10.54 $5.50 1.92
2019-06-30 14.56 $5.25 2.77
2019-03-31 14.03 $4.97 2.82
2018-12-31 17.45 $4.73 3.69
2018-09-30 15.24 $3.95 3.86
2018-06-30 13.80 $3.30 4.18
2018-03-31 16.67 $2.82 5.90
2017-12-31 14.19 $2.62 5.43
2017-09-30 14.12 $1.93 7.33
2017-06-30 12.80 $1.47 8.73
2017-03-31 13.83 $1.21 11.46
2016-12-31 10.70 $1.04 10.29
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.370B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $391.238B 18.65
Roche Holding AG (RHHBY) Switzerland $294.553B 0.00
Pfizer (PFE) United States $213.662B 13.35
Merck (MRK) United States $204.919B 14.63
Novartis AG (NVS) Switzerland $189.756B 14.75
AbbVie (ABBV) United States $163.988B 9.99
Novo Nordisk (NVO) Denmark $152.214B 24.77
Eli Lilly (LLY) United States $146.273B 22.33
AstraZeneca (AZN) United Kingdom $145.417B 28.27
Sanofi (SNY) $128.988B 15.33
GlaxoSmithKline (GSK) United Kingdom $102.323B 13.42
Bayer (BAYRY) Germany $61.403B 8.85
H Lundbeck (HLUYY) Denmark $7.388B 0.00